iBio, Inc.IBIO
What iBio, Inc. does.
iBio, Inc. (also referred to as “we”, “us”, “our”, “iBio”, or the “Company”) is a clinical-stage biotechnology company leveraging the power of Artificial Intelligence (“AI”) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic and cardiopulmonary diseases. Our core mission is to harness the potential of AI and machine learning (“ML”) to unveil novel biologics which other scientists have been unable to develop. Through our innovative AI Drug Discovery Platform, we have been able to identify differentiated molecules aimed at addressing unmet needs by current approved therapies.
We believe the future treatment for obesity lies not just in overall weight loss, but in the quality, durability, and tolerability of weight loss. Current interventional therapies, such as glucagon-like peptide-1 (“GLP-1”) receptor agonists have ushered in a breakthrough era, yet challenges remain: muscle loss, fat regain after treatment cessation, and long-term tolerability. We are developing next-generation therapies designed with the goal of meeting these unmet needs, by leveraging AI-guided antibody design, advanced screening technologies and deep expertise in biologics development.
Revenue and profit, by fiscal year.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Revenue | $2.4M | $1.9M | $0 | $225,000 | $400,000 | $100,000 |
| Net income | -$23.2M | -$50.3M | -$65.0M | -$24.9M | -$18.4M | -$33.0M |
| Free cash flow | -$35.0M | -$44.8M | -$36.2M | -$18.8M | -$15.3M | -$23.8M |
More on IBIO.
- iBio, Inc. summary
- iBio, Inc. financial statements
- iBio, Inc. key metrics
- iBio, Inc. health scores and style box
- iBio, Inc. earnings
- iBio, Inc. dividends
- iBio, Inc. valuation
- iBio, Inc. ownership and insiders
- iBio, Inc. peers
Figures from iBio, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.